{ "labelLang" : "hun", "responseDate" : "2024-03-28 11:52", "content" : { "otype" : "JournalArticle", "mtid" : 31386677, "status" : "VALIDATED", "published" : true, "comment" : "Funding Agency and Grant Number: Ministry of Health and WelfareMinistry of Health, Labour and Welfare, Japan [MOHW109-TDU-B-211-114001]; Taipei Veterans General HospitalTaipei Veterans General Hospital [109DHA0100196]\n Funding text: This work was supported, in part, by grants from the Ministry of Health and Welfare (MOHW109-TDU-B-211-114001), and intramural grants from the Taipei Veterans General Hospital (109DHA0100196).\nGeneral Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan \n Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan \n School of Medicine, National Yang-Ming University, Taipei, Taiwan \n Center for Evidence-based Medicine, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan \n Cited By :1 \n Export Date: 31 August 2020 \n CODEN: JCMAB \n Correspondence Address: Chiang, C.-E.; General Clinical Research Center, Department of Medical Research, Taipei Veterans General Hospital, 201, Section 2, Shi-Pai Road, Taiwan; email: cechiang@vghtpe.gov.tw \n Chemicals/CAS: acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; albiglutide, 782500-75-8; alogliptin, 850649-61-5, 850649-62-6; canagliflozin, 842133-18-0, 928672-86-0; colchicine, 64-86-8; dapagliflozin, 461432-26-8; dulaglutide, 923950-08-7; empagliflozin, 864070-44-0; exendin 4, 141732-76-5, 141758-74-9; linagliptin, 668270-12-0; liraglutide, 204656-20-2; lixisenatide, 320367-13-3; metformin, 1115-70-4, 657-24-9; minoxidil, 38304-91-5; rituximab, 174722-31-7; sacubitril plus valsartan, 936623-90-4; saxagliptin, 361442-04-8, 945667-22-1; semaglutide, 910463-68-2; sildenafil, 139755-83-2; sitagliptin, 486460-32-6, 654671-78-0, 654671-77-9\nGeneral Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan \n Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan \n School of Medicine, National Yang-Ming University, Taipei, Taiwan \n Center for Evidence-based Medicine, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan \n Cited By :1 \n Export Date: 8 December 2020 \n CODEN: JCMAB \n Correspondence Address: Chiang, C.-E.; General Clinical Research Center, Department of Medical Research, Taipei Veterans General Hospital, 201, Section 2, Shi-Pai Road, Taiwan; email: cechiang@vghtpe.gov.tw\nGeneral Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan \n Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan \n School of Medicine, National Yang-Ming University, Taipei, Taiwan \n Center for Evidence-based Medicine, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan \n Cited By :2 \n Export Date: 20 January 2021 \n CODEN: JCMAB \n Correspondence Address: Chiang, C.-E.; General Clinical Research Center, Department of Medical Research, Taipei Veterans General Hospital, 201, Section 2, Shi-Pai Road, Taiwan; email: cechiang@vghtpe.gov.tw\nGeneral Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan \n Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan \n School of Medicine, National Yang-Ming University, Taipei, Taiwan \n Center for Evidence-based Medicine, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan \n Cited By :2 \n Export Date: 16 February 2021 \n CODEN: JCMAB \n Correspondence Address: Chiang, C.-E.; General Clinical Research Center, 201, Section 2, Shi-Pai Road, Taiwan; email: cechiang@vghtpe.gov.tw \n Chemicals/CAS: acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; albiglutide, 782500-75-8; alogliptin, 850649-61-5, 850649-62-6; canagliflozin, 842133-18-0, 928672-86-0; colchicine, 64-86-8; dapagliflozin, 461432-26-8; dulaglutide, 923950-08-7; empagliflozin, 864070-44-0; exendin 4, 141732-76-5, 141758-74-9; linagliptin, 668270-12-0; liraglutide, 204656-20-2; lixisenatide, 320367-13-3; metformin, 1115-70-4, 657-24-9; minoxidil, 38304-91-5; rituximab, 174722-31-7; sacubitril plus valsartan, 936623-90-4; saxagliptin, 361442-04-8, 945667-22-1; semaglutide, 910463-68-2; sildenafil, 139755-83-2; sitagliptin, 486460-32-6, 654671-78-0, 654671-77-9\nGeneral Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan \n Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan \n School of Medicine, National Yang-Ming University, Taipei, Taiwan \n Center for Evidence-based Medicine, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan \n Cited By :2 \n Export Date: 18 April 2021 \n CODEN: JCMAB \n Correspondence Address: Chiang, C.-E.; General Clinical Research Center, 201, Section 2, Shi-Pai Road, Taiwan; email: cechiang@vghtpe.gov.tw\nGeneral Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan \n Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan \n School of Medicine, National Yang-Ming University, Taipei, Taiwan \n Center for Evidence-based Medicine, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan \n Cited By :2 \n Export Date: 19 May 2021 \n CODEN: JCMAB \n Correspondence Address: Chiang, C.-E.; General Clinical Research Center, 201, Section 2, Shi-Pai Road, Taiwan; email: cechiang@vghtpe.gov.tw \n Chemicals/CAS: acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; albiglutide, 782500-75-8; alogliptin, 850649-61-5, 850649-62-6; canagliflozin, 842133-18-0, 928672-86-0; colchicine, 64-86-8; dapagliflozin, 461432-26-8; dulaglutide, 923950-08-7; empagliflozin, 864070-44-0; exendin 4, 141732-76-5, 141758-74-9; linagliptin, 668270-12-0; liraglutide, 204656-20-2; lixisenatide, 320367-13-3; metformin, 1115-70-4, 657-24-9; minoxidil, 38304-91-5; rituximab, 174722-31-7; sacubitril plus valsartan, 936623-90-4; saxagliptin, 361442-04-8, 945667-22-1; semaglutide, 910463-68-2; sildenafil, 139755-83-2; sitagliptin, 486460-32-6, 654671-78-0, 654671-77-9\nGeneral Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan \n Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan \n School of Medicine, National Yang-Ming University, Taipei, Taiwan \n Center for Evidence-based Medicine, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan \n Cited By :2 \n Export Date: 9 July 2021 \n CODEN: JCMAB \n Correspondence Address: Chiang, C.-E.; General Clinical Research Center, 201, Section 2, Shi-Pai Road, Taiwan; email: cechiang@vghtpe.gov.tw \n Chemicals/CAS: acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; albiglutide, 782500-75-8; alogliptin, 850649-61-5, 850649-62-6; canagliflozin, 842133-18-0, 928672-86-0; colchicine, 64-86-8; dapagliflozin, 461432-26-8; dulaglutide, 923950-08-7; empagliflozin, 864070-44-0; exendin 4, 141732-76-5, 141758-74-9; linagliptin, 668270-12-0; liraglutide, 204656-20-2; lixisenatide, 320367-13-3; metformin, 1115-70-4, 657-24-9; minoxidil, 38304-91-5; rituximab, 174722-31-7; sacubitril plus valsartan, 936623-90-4; saxagliptin, 361442-04-8, 945667-22-1; semaglutide, 910463-68-2; sildenafil, 139755-83-2; sitagliptin, 486460-32-6, 654671-78-0, 654671-77-9", "unhandledTickets" : 0, "deleted" : false, "lastRefresh" : "2024-03-20T15:35:45.914+0000", "lastModified" : "2020-08-05T13:07:23.169+0000", "created" : "2020-07-23T08:24:23.768+0000", "creator" : { "otype" : "Admin", "mtid" : 10071338, "link" : "/api/admin/10071338", "label" : "Molnár-Taga Márta (SE_AOK_1Bel_Onkol_Admin5_MTM, admin)", "familyName" : "Molnár-Taga", "givenName" : "Márta", "published" : true, "snippet" : true }, "lastDuplumOK" : "2024-03-18T12:02:50.240+0000", "lastDuplumSearch" : "2024-03-18T12:02:50.240+0000", "validated" : "2020-08-27T02:37:44.116+0000", "validator" : { "otype" : "Admin", "mtid" : 565, "link" : "/api/admin/565", "label" : "WoS import (admin)", "familyName" : "WoS", "givenName" : "import", "published" : true, "snippet" : true }, "core" : false, "citation" : true, "publicationPending" : false, "type" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "subType" : { "otype" : "SubType", "mtid" : 10000059, "link" : "/api/subtype/10000059", "label" : "Szakcikk (Folyóiratcikk)", "name" : "Szakcikk", "nameEng" : "Article", "docType" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "listPosition" : 101, "published" : true, "oldId" : 10000059, "snippet" : true }, "category" : { "otype" : "Category", "mtid" : 1, "link" : "/api/category/1", "label" : "Tudományos", "published" : true, "oldId" : 1, "snippet" : true }, "languages" : [ { "otype" : "Language", "mtid" : 10002, "link" : "/api/language/10002", "label" : "Angol", "name" : "Angol", "nameEng" : "English", "published" : true, "oldId" : 2, "snippet" : true } ], "firstAuthor" : "Chiang, C.-E.", "authorships" : [ { "otype" : "PersonAuthorship", "mtid" : 92197395, "link" : "/api/authorship/92197395", "label" : "Chiang, C.-E. ✉", "listPosition" : 1, "share" : 0.0, "first" : true, "last" : false, "corresponding" : true, "familyName" : "Chiang", "givenName" : "C.-E.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 92197396, "link" : "/api/authorship/92197396", "label" : "Wang, K.-L.", "listPosition" : 2, "share" : 0.0, "first" : false, "last" : false, "corresponding" : false, "familyName" : "Wang", "givenName" : "K.-L.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 92197397, "link" : "/api/authorship/92197397", "label" : "Cheng, H.-M.", "listPosition" : 3, "share" : 0.0, "first" : false, "last" : false, "corresponding" : false, "familyName" : "Cheng", "givenName" : "H.-M.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 92197398, "link" : "/api/authorship/92197398", "label" : "Sung, S.-H.", "listPosition" : 4, "share" : 0.0, "first" : false, "last" : false, "corresponding" : false, "familyName" : "Sung", "givenName" : "S.-H.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 92197399, "link" : "/api/authorship/92197399", "label" : "Chao, T.-F.", "listPosition" : 5, "share" : 0.0, "first" : false, "last" : true, "corresponding" : false, "familyName" : "Chao", "givenName" : "T.-F.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true } ], "title" : "Second revolution in cardiovascular prevention", "identifiers" : [ { "otype" : "PublicationIdentifier", "mtid" : 17076135, "link" : "/api/publicationidentifier/17076135", "label" : "DOI: 10.1097/JCMA.0000000000000276", "source" : { "otype" : "PlainSource", "mtid" : 6, "link" : "/api/publicationsource/6", "label" : "DOI", "type" : { "otype" : "PublicationSourceType", "mtid" : 10001, "link" : "/api/publicationsourcetype/10001", "label" : "DOI", "mayHaveOa" : true, "published" : true, "snippet" : true }, "name" : "DOI", "nameEng" : "DOI", "linkPattern" : "https://doi.org/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 6, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "10.1097/JCMA.0000000000000276", "realUrl" : "https://doi.org/10.1097/JCMA.0000000000000276", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 17076136, "link" : "/api/publicationidentifier/17076136", "label" : "WoS: 000528845500005", "source" : { "otype" : "PlainSource", "mtid" : 1, "link" : "/api/publicationsource/1", "label" : "WoS", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "WoS", "nameEng" : "WoS", "linkPattern" : "https://www.webofscience.com/wos/woscc/full-record/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 1, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "000528845500005", "realUrl" : "https://www.webofscience.com/wos/woscc/full-record/000528845500005", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 17076134, "link" : "/api/publicationidentifier/17076134", "label" : "Scopus: 85082881651", "source" : { "otype" : "PlainSource", "mtid" : 3, "link" : "/api/publicationsource/3", "label" : "Scopus", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "Scopus", "linkPattern" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@", "publiclyVisible" : true, "published" : true, "oldId" : 3, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "85082881651", "realUrl" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85082881651", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 17076516, "link" : "/api/publicationidentifier/17076516", "label" : "PubMed: 32101893", "source" : { "otype" : "PlainSource", "mtid" : 17, "link" : "/api/publicationsource/17", "label" : "PubMed", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "PubMed", "nameEng" : "PubMed", "linkPattern" : "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract", "publiclyVisible" : true, "published" : true, "oldId" : 17, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "32101893", "realUrl" : "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32101893&dopt=Abstract", "published" : false, "snippet" : true } ], "journal" : { "otype" : "Journal", "mtid" : 10015722, "link" : "/api/journal/10015722", "label" : "JOURNAL OF THE CHINESE MEDICAL ASSOCIATION 1726-4901 1728-7731", "pIssn" : "1726-4901", "eIssn" : "1728-7731", "reviewType" : "REVIEWED", "noIF" : false, "sciIndexed" : true, "scopusIndexed" : true, "lang" : "FOREIGN", "hungarian" : false, "published" : true, "oldId" : 10015722, "snippet" : true }, "volume" : "83", "issue" : "4", "firstPage" : "327", "lastPage" : "336", "firstPageOrInternalIdForSort" : "327", "pageLength" : 10, "publishedYear" : 2020, "abstractText" : "Type 2 diabetes has become a major disease burden in twenty-first century. Both incidence and prevalence of type 2 diabetes have quadrupled between 1980 and 2004 in the whole world. Atherosclerotic cardiovascular disease (ASCVD) is the major complication of type 2 diabetes. The introduction of statins in clinical settings is the first revolution in our battle against ASCVD. Most ASCVDs could be prevented or treated with statins. However, statin failed to reduce chronic kidney diseases (CKD) and heart failure (HF). Owing to a mandate from US Food and Drug Administration in 2008 that every new antidiabetic drug should be tested in clinical trials to demonstrate its safety, we now have a good opportunity to look for better antidiabetic drugs not only to decrease blood sugar but also to decrease CVD or renal disease. Among them, glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors (SGLT-2 i) are two most extensively studied ones. SGLT-2 i, in particular, prevent CKD and end-stage renal disease, and prevent HF. In the recent CREDENCE trial, canagliflozin reduced renal endpoints by 34% and end-stage renal disease by 32%. Furthermore, in the recent DAPA-HF trial, dapagliflozin decreased hospitalization for HF/ cardiovascular death by 26%, and total death by 17%, in patients with HF with reduced ejection fraction, irrespective of diabetes or nondiabetes. The beneficial effects of SGLT-2 i in CKD and HF are complementary to the effects of statins. The introduction of SGLT-2 i in clinical practice is the second revolution in cardiovascular prevention. Copyright © 2020, the Chinese Medical Association.", "keywords" : [ { "otype" : "Keyword", "mtid" : 14018, "link" : "/api/keyword/14018", "label" : "heart failure", "published" : true, "oldId" : 14018, "snippet" : true }, { "otype" : "Keyword", "mtid" : 14110, "link" : "/api/keyword/14110", "label" : "Diabetes Mellitus, Type 2", "published" : true, "oldId" : 14110, "snippet" : true }, { "otype" : "Keyword", "mtid" : 14235, "link" : "/api/keyword/14235", "label" : "cardiovascular disease", "published" : true, "oldId" : 14235, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1036143, "link" : "/api/keyword/1036143", "label" : "Renal Insufficiency", "published" : true, "oldId" : 1036143, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1498265, "link" : "/api/keyword/1498265", "label" : "chronic", "published" : true, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1828319, "link" : "/api/keyword/1828319", "label" : "Sodium-glucose transporter 2 inhibitors", "published" : true, "snippet" : true } ], "digital" : null, "printed" : null, "sourceYear" : 2020, "foreignEdition" : true, "foreignLanguage" : true, "fullPublication" : true, "conferencePublication" : false, "nationalOrigin" : false, "missingAuthor" : false, "oaType" : "NONE", "oaCheckDate" : "2024-03-20", "oaFree" : false, "citationCount" : 0, "citationCountUnpublished" : 0, "citationCountWoOther" : 0, "independentCitCountWoOther" : 0, "doiCitationCount" : 0, "wosCitationCount" : 0, "scopusCitationCount" : 0, "independentCitationCount" : 0, "unhandledCitationCount" : 0, "citingPubCount" : 0, "independentCitingPubCount" : 0, "unhandledCitingPubCount" : 0, "citedPubCount" : 21, "citedCount" : 21, "ratings" : [ { "otype" : "SjrRating", "mtid" : 10994135, "link" : "/api/sjrrating/10994135", "label" : "sjr:Q3 (2020) Scopus - Medicine (miscellaneous) JOURNAL OF THE CHINESE MEDICAL ASSOCIATION 1726-4901", "listPos" : 1248, "rankValue" : 0.74, "type" : "journal", "ratingType" : { "otype" : "RatingType", "mtid" : 10002, "link" : "/api/ratingtype/10002", "label" : "sjr", "code" : "sjr", "published" : true, "snippet" : true }, "subject" : { "otype" : "ClassificationExternal", "mtid" : 2701, "link" : "/api/classificationexternal/2701", "label" : "Scopus - Medicine (miscellaneous)", "published" : true, "oldId" : 2701, "snippet" : true }, "ranking" : "Q3", "calculation" : "DIRECT", "published" : true, "snippet" : true } ], "ratingsForSort" : "Q3", "referenceList" : "Mensah, GA, Roth, GA, Fuster, V., The global burden of cardiovascular diseases and risk factors: 2020 and beyond (2019) J Am Coll Cardiol, 74, pp. 2529-2532 ;\n Rawshani, A, Rawshani, A, Franzén, S, Sattar, N, Eliasson, B, Svensson, AM, Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes (2018) N Engl J Med, 379, pp. 633-644 ;\n Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants (2016) Lancet, 387, pp. 1513-1530. , Collaboration NCDRF ;\n Chatterjee, S, Khunti, K, Davies, MJ., Type 2 diabetes (2017) Lancet, 389, pp. 2239-2251 ;\n Low Wang, CC, Hess, CN, Hiatt, WR, Goldfine, AB., Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations (2016) Circulation, 133, pp. 2459-2502 ;\n Booth, GL, Kapral, MK, Fung, K, Tu, JV., Relation between age and cardiovascular disease in men and women with diabetes compared with nondiabetic people: a population-based retrospective cohort study (2006) Lancet, 368, pp. 29-36 ;\n Baigent, C, Blackwell, L, Emberson, J, Holland, LE, Reith, C, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials (2010) Lancet, 376, pp. 1670-1681. , Cholesterol Treatment Trialists (CTT) Collaboration ;\n Wanner, C, Krane, V, März, W, Olschewski, M, Mann, JF, Ruf, G, Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis (2005) N Engl J Med, 353, pp. 238-248. , German Diabetes and Dialysis Study Investigators ;\n Fellström, BC, Jardine, AG, Schmieder, RE, Holdaas, H, Bannister, K, Beutler, J, Rosuvastatin and cardiovascular events in patients undergoing hemodialysis (2009) N Engl J Med, 360, pp. 1395-1407. , AURORA Study Group ;\n Tavazzi, L, Maggioni, AP, Marchioli, R, Barlera, S, Franzosi, MG, Latini, R, Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial (2008) Lancet, 372, pp. 1231-1239. , Gissi-HF Investigators ;\n Kjekshus, J, Apetrei, E, Barrios, V, Böhm, M, Cleland, JG, Cornel, JH, Rosuvastatin in older patients with systolic heart failure (2007) N Engl J Med, 357, pp. 2248-2261. , CORONA Group ;\n Lai, CL, Chou, HW, Chan, KA, Lai, MS., Effects of atorvastatin and rosuvastatin on renal function in patients with type 2 diabetes mellitus (2015) Am J Cardiol, 115, pp. 619-624 ;\n Strippoli, GF, Navaneethan, SD, Johnson, DW, Perkovic, V, Pellegrini, F, Nicolucci, A, Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials (2008) BMJ, 336, pp. 645-651 ;\n Baigent, C, Landray, MJ, Reith, C, Emberson, J, Wheeler, DC, Tomson, C, The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial (2011) Lancet, 377, pp. 2181-2192. , SHARP Investigators ;\n Yusuf, S, Bosch, J, Dagenais, G, Zhu, J, Xavier, D, Liu, L, Cholesterol lowering in intermediate-risk persons without cardiovascular disease (2016) N Engl J Med, 374, pp. 2021-2031. , HOPE-3 Investigators ;\n Seferović, PM, Paulus, WJ., Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes (2015) Eur Heart J, 36, pp. 1718a-1727c ;\n Seferović, PM, Petrie, MC, Filippatos, GS, Anker, SD, Rosano, G, Bauersachs, J, Type 2 diabetes mellitus and heart failure: a position statement from the heart failure association of the European Society of Cardiology (2018) Eur J Heart Fail, 20, pp. 853-872 ;\n Chia, YMF, Teng, TK, Tay, WT, Anand, I, MacDonald, MR, Yap, J, Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus (2019) Eur J Heart Fail, 21, pp. 685-688. , ASIAN-HF Investigators ;\n Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) (1998) Lancet, 352, pp. 837-853. , UKPDS Group ;\n Gerstein, HC, Miller, ME, Byington, RP, Goff, DC, Bigger, JT, Effects of intensive glucose lowering in type 2 diabetes (2008) N Engl J Med, 358, pp. 2545-2559. , Action to Control Cardiovascular Risk in Diabetes Study Group ;\n Patel, A, MacMahon, S, Chalmers, J, Neal, B, Billot, L, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes (2008) N Engl J Med, 358, pp. 2560-2572. , ADVANCE Collaborative Group ;\n Duckworth, W, Abraira, C, Moritz, T, Reda, D, Emanuele, N, Reaven, PD, Glucose control and vascular complications in veterans with type 2 diabetes (2009) N Engl J Med, 360, pp. 129-139. , VADT Investigators ;\n Holman, RR, Paul, SK, Bethel, MA, Matthews, DR, Neil, HA., 10-year follow-up of intensive glucose control in type 2 diabetes (2008) N Engl J Med, 359, pp. 1577-1589 ;\n Gerstein, HC, Miller, ME, Ismail-Beigi, F, Largay, J, McDonald, C, Lochnan, HA, Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial (2014) Lancet, 384, pp. 1936-1941. , ACCORD Study Group ;\n Zoungas, S, Chalmers, J, Neal, B, Billot, L, Li, Q, Hirakawa, Y, Follow-up of blood-pressure lowering and glucose control in type 2 diabetes (2014) N Engl J Med, 371, pp. 1392-1406. , ADVANCE-ON Collaborative Group ;\n Hayward, RA, Reaven, PD, Wiitala, WL, Bahn, GD, Reda, DJ, Ge, L, Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes (2015) N Engl J Med, 372, pp. 2197-2206. , VADT Investigators ;\n Dormandy, JA, Charbonnel, B, Eckland, DJ, Erdmann, E, Massi-Benedetti, M, Moules, IK, Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial (2005) Lancet, 366, pp. 1279-1289. , PROactive Investigators ;\n Ray, KK, Seshasai, SR, Wijesuriya, S, Sivakumaran, R, Nethercott, S, Preiss, D, Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials (2009) Lancet, 373, pp. 1765-1772 ;\n Huang, CJ, Wang, WT, Sung, SH, Chen, CH, Lip, GYH, Cheng, HM, Blood glucose reduction by diabetic drugs with minimal hypoglycaemia risk for cardiovascular outcomes: evidence from meta-regression analysis of randomized controlled trials (2018) Diabetes Obes Metab, 20, pp. 2131-2139 ;\n Nissen, SE, Wolski, K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes (2007) N Engl J Med, 356, pp. 2457-2471 ;\n Holman, RR, Sourij, H, Califf, RM., Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes (2014) Lancet, 383, pp. 2008-2017 ;\n Scirica, BM, Bhatt, DL, Braunwald, E, Steg, PG, Davidson, J, Hirshberg, B, Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus (2013) N Engl J Med, 369, pp. 1317-1326. , SAVOR-TIMI 53 Steering Committee and Investigators ;\n White, WB, Cannon, CP, Heller, SR, Nissen, SE, Bergenstal, RM, Bakris, GL, Alogliptin after acute coronary syndrome in patients with type 2 diabetes (2013) N Engl J Med, 369, pp. 1327-1335. , EXAMINE Investigators ;\n Green, JB, Bethel, MA, Armstrong, PW, Buse, JB, Engel, SS, Garg, J, Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes (2015) N Engl J Med, 373, pp. 232-242. , TECOS Study Group ;\n Rosenstock, J, Perkovic, V, Johansen, OE, Cooper, ME, Kahn, SE, Marx, N, Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial (2019) JAMA, 321, pp. 69-79. , CARMELINA Investigators ;\n Pfeffer, MA, Claggett, B, Diaz, R, Dickstein, K, Gerstein, HC, Køber, LV, Lixisenatide in patients with type 2 diabetes and acute coronary syndrome (2015) N Engl J Med, 373, pp. 2247-2257. , ELIXA Investigators ;\n Holman, RR, Bethel, MA, Mentz, RJ, Thompson, VP, Lokhnygina, Y, Buse, JB, Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (2017) N Engl J Med, 377, pp. 1228-1239. , EXSCEL Study Group ;\n Marso, SP, Daniels, GH, Brown-Frandsen, K, Kristensen, P, Mann, JF, Nauck, MA, Liraglutide and cardiovascular outcomes in type 2 diabetes (2016) N Engl J Med, 375, pp. 311-322. , LEADER Steering Committee ;\n LEADER Trial Investigators ;\n Marso, SP, Bain, SC, Consoli, A, Eliaschewitz, FG, Jódar, E, Leiter, LA, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (2016) N Engl J Med, 375, pp. 1834-1844. , SUSTAIN-6 Investigators ;\n Husain, M, Birkenfeld, AL, Donsmark, M, Dungan, K, Eliaschewitz, FG, Franco, DR, Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes (2019) N Engl J Med, 381, pp. 841-851. , PIONEER 6 Investigators ;\n Hernandez, AF, Green, JB, Janmohamed, S, D’Agostino, RB, Granger, CB, Jones, NP, Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial (2018) Lancet, 392, pp. 1519-1529. , Harmony Outcomes committees and investigators ;\n Gerstein, HC, Colhoun, HM, Dagenais, GR, Diaz, R, Lakshmanan, M, Pais, P, Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial (2019) Lancet, 394, pp. 121-130. , REWIND Investigators ;\n Giugliano, D, Maiorino, MI, Bellastella, G, Longo, M, Chiodini, P, Esposito, K., GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis including the REWIND and PIONEER 6 trials (2019) Diabetes Obes Metab, 21, pp. 2576-2580 ;\n Bays, H., From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus (2009) Curr Med Res Opin, 25, pp. 671-681 ;\n Ferrannini, E, Solini, A., SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects (2012) Nat Rev Endocrinol, 8, pp. 495-502 ;\n Bakris, GL, Fonseca, VA, Sharma, K, Wright, EM., Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications (2009) Kidney Int, 75, pp. 1272-1277 ;\n Kario, K, Okada, K, Kato, M, Nishizawa, M, Yoshida, T, Asano, T, 24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study (2018) Circulation, 139, pp. 2089-2097 ;\n Karg, MV, Bosch, A, Kannenkeril, D, Striepe, K, Ott, C, Schneider, MP, SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial (2018) Cardiovasc Diabetol, 17, p. 5 ;\n Verma, SM, McMurray, JJV., SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review (2018) Diabetologia, 61, pp. 2108-2117 ;\n Hallow, KM, Helmlinger, G, Greasley, PJ, McMurray, JJV, Boulton, DW., Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis (2018) Diabetes Obes Metab, 20, pp. 479-487 ;\n Verma, S, Garg, A, Yan, AT, Gupta, AK, Al-Omran, M, Sabongui, A, Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial? (2016) Diabetes Care, 39, pp. e212-e213 ;\n Uthman, L, Baartscheer, A, Bleijlevens, B, Schumacher, CA, Fiolet, JWT, Koeman, A, Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation (2018) Diabetologia, 61, pp. 722-726 ;\n Uthman, L, Nederlof, R, Eerbeek, O, Baartscheer, A, Schumacher, C, Buchholtz, N, Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts (2019) Cardiovasc Res, 115, pp. 1533-1545 ;\n Baartscheer, A, Schumacher, CA, Wüst, RC, Fiolet, JW, Stienen, GJ, Coronel, R, Empagliflozin decreases myocardial cytoplasmic na+ through inhibition of the cardiac na+/H+ exchanger in rats and rabbits (2017) Diabetologia, 60, pp. 568-573 ;\n Packer, M., Reconceptualization of the molecular mechanism by which sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure events (2019) Circulation, 140, pp. 443-445 ;\n Zelniker, TA, Braunwald, E., Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC State-of-the-Art review (2020) J Am Coll Cardiol, 75, pp. 422-434 ;\n Kidokoro, K, Cherney, DZI, Bozovic, A, Nagasu, H, Satoh, M, Kanda, E, Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging (2019) Circulation, 140, pp. 303-315 ;\n Wanner, C., Sodium glucose cotransporter 2 inhibition and the visualization of kidney hemodynamics (2019) Circulation, 140, pp. 316-318 ;\n Januzzi, JL, Butler, J, Jarolim, P, Sattar, N, Vijapurkar, U, Desai, M, Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes (2017) J Am Coll Cardiol, 70, pp. 704-712 ;\n Santos-Gallego, CG, Requena-Ibanez, JA, San Antonio, R, Ishikawa, K, Watanabe, S, Picatoste, B, Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics (2019) J Am Coll Cardiol, 73, pp. 1931-1944 ;\n Zinman, B, Wanner, C, Lachin, JM, Fitchett, D, Bluhmki, E, Hantel, S, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (2015) N Engl J Med, 373, pp. 2117-2128. , EMPA-REG OUTCOME Investigators ;\n Neal, B, Perkovic, V, Mahaffey, KW, de Zeeuw, D, Fulcher, G, Erondu, N, Canagliflozin and cardiovascular and renal events in type 2 diabetes (2017) N Engl J Med, 377, pp. 644-657. , CANVAS Program Collaborative Group ;\n Wiviott, SD, Raz, I, Bonaca, MP, Mosenzon, O, Kato, ET, Cahn, A, Dapagliflozin and cardiovascular outcomes in type 2 diabetes (2019) N Engl J Med, 380, pp. 347-357. , DECLARE–TIMI 58 Investigators ;\n Perkovic, V, Jardine, MJ, Neal, B, Bompoint, S, Heerspink, HJL, Charytan, DM, Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (2019) N Engl J Med, 380, pp. 2295-2306. , CREDENCE Trial Investigators ;\n Liyanage, T, Ninomiya, T, Jha, V, Neal, B, Patrice, HM, Okpechi, I, Worldwide access to treatment for end-stage kidney disease: a systematic review (2015) Lancet, 385, pp. 1975-1982 ;\n Mosenzon, O, Wiviott, SD, Cahn, A, Rozenberg, A, Yanuv, I, Goodrich, EL, Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial (2019) Lancet Diabetes Endocrinol, 7, pp. 606-617 ;\n Brenner, BM, Cooper, ME, de Zeeuw, D, Keane, WF, Mitch, WE, Parving, HH, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (2001) N Engl J Med, 345, pp. 861-869. , RENAAL Study Investigators ;\n Lewis, EJ, Hunsicker, LG, Clarke, WR, Berl, T, Pohl, MA, Lewis, JB, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes (2001) N Engl J Med, 345, pp. 851-860. , Collaborative Study Group ;\n Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2020 (2020) Diabetes Care, 43, pp. S98-S110. , American Diabetes A. 9 ;\n Nichols, GA, Gullion, CM, Koro, CE, Ephross, SA, Brown, JB., The incidence of congestive heart failure in type 2 diabetes: an update (2004) Diabetes Care, 27, pp. 1879-1884 ;\n Burrows, NR, Li, Y, Gregg, EW, Geiss, LS., Declining rates of hospitalization for selected cardiovascular disease conditions among adults aged ≥35 years with diagnosed diabetes, U.S., 1998-2014 (2018) Diabetes Care, 41, pp. 293-302 ;\n Nichols, GA, Hillier, TA, Erbey, JR, Brown, JB., Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors (2001) Diabetes Care, 24, pp. 1614-1619 ;\n Thrainsdottir, IS, Aspelund, T, Thorgeirsson, G, Gudnason, V, Hardarson, T, Malmberg, K, The association between glucose abnormalities and heart failure in the population-based Reykjavik study (2005) Diabetes Care, 28, pp. 612-616 ;\n Cavender, MA, Steg, PG, Smith, SC, Eagle, K, Ohman, EM, Goto, S, Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) registry (2015) Circulation, 132, pp. 923-931. , REACH Registry Investigators ;\n Bertoni, AG, Hundley, WG, Massing, MW, Bonds, DE, Burke, GL, Goff, DC, Heart failure prevalence, incidence, and mortality in the elderly with diabetes (2004) Diabetes Care, 27, pp. 699-703 ;\n Berg, DD, Wiviott, SD, Scirica, BM, Gurmu, Y, Mosenzon, O, Murphy, SA, Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus (2019) Circulation, 140, pp. 1569-1577 ;\n Kato, ET, Silverman, MG, Mosenzon, O, Zelniker, TA, Cahn, A, Furtado, RHM, Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus (2019) Circulation, 139, pp. 2528-2536 ;\n McMurray, JJV, Solomon, SD, Inzucchi, SE, Køber, L, Kosiborod, MN, Martinez, FA, Dapagliflozin in patients with heart failure and reduced ejection fraction (2019) N Engl J Med, 381, pp. 1995-2008. , DAPA-HF Trial Committees and Investigators ;\n Martinez, FA, Serenelli, M, Nicolau, JC, Petrie, MC, Chiang, CE, Tereshchenko, S, Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF (2020) Circulation, 141, pp. 100-111 ;\n Kosiborod, MN, Jhund, PS, Docherty, KF, Diez, M, Petrie, MC, Verma, S, Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial (2020) Circulation, 141, pp. 90-99 ;\n Ponikowski, P, Voors, AA, Anker, SD, Bueno, H, Cleland, JGF, Coats, AJS, 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC (2016) Eur Heart J, 37, pp. 2129-2200. , ESC Scientific Document Group ;\n Yancy, CW, Jessup, M, Bozkurt, B, Butler, J, Casey, DE, Colvin, MM, 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America (2016) J Am Coll Cardiol, 68, pp. 1476-1488 ;\n McMurray, JJ, Packer, M, Desai, AS, Gong, J, Lefkowitz, MP, Rizkala, AR, Angiotensinneprilysin inhibition versus enalapril in heart failure (2014) N Engl J Med, 371, pp. 993-1004. , PARADIGM-HF Investigators and Committees ;\n Zelniker, TA, Wiviott, SD, Raz, I, Im, K, Goodrich, EL, Furtado, RHM, Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus (2019) Circulation, 139, pp. 2022-2031 ;\n Zelniker, TA, Wiviott, SD, Raz, I, Im, K, Goodrich, EL, Bonaca, MP, SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials (2019) Lancet, 393, pp. 31-39 ;\n Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) (1998) Lancet, 352, pp. 854-865. , Group UKPDS ;\n Roussel, R, Travert, F, Pasquet, B, Wilson, PW, Smith, SC, Goto, S, Metformin use and mortality among patients with diabetes and atherothrombosis (2010) Arch Intern Med, 170, pp. 1892-1899. , Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators ;\n Eurich, DT, Weir, DL, Majumdar, SR, Tsuyuki, RT, Johnson, JA, Tjosvold, L, Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients (2013) Circ Heart Fail, 6, pp. 395-402 ;\n Crowley, MJ, Diamantidis, CJ, McDuffie, JR, Cameron, CB, Stanifer, JW, Mock, CK, Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: A systematic review (2017) Ann Intern Med, 166, pp. 191-200 ;\n Bergmark, BA, Bhatt, DL, McGuire, DK, Cahn, A, Mosenzon, O, Steg, PG, Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 trial (2019) Circulation, 140, pp. 1004-1014. , SAVOR-TIMI 53 Steering Committee and Investigators ;\n Cosentino, F, Grant, PJ, Aboyans, V, Bailey, CJ, Ceriello, A, Delgado, V, 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD (2020) Eur Heart J, 41, pp. 255-323. , ESC Scientific Document Group", "hasCitationDuplums" : false, "userChangeableUntil" : "2020-09-15T13:28:53.812+0000", "directInstitutesForSort" : "", "ownerAuthorCount" : 45, "ownerInstituteCount" : 113, "directInstituteCount" : 0, "authorCount" : 5, "contributorCount" : 0, "hasQualityFactor" : true, "link" : "/api/publication/31386677", "label" : "Chiang C.-E. et al. Second revolution in cardiovascular prevention. (2020) JOURNAL OF THE CHINESE MEDICAL ASSOCIATION 1726-4901 1728-7731 83 4 327-336", "template" : "